I’m torn with this approach vs cash certainty. Constantly raising in this type of market is really tough and short term movements in share price can often result in dilutions anyway. I would rather the company has sufficient run way and a strong balance sheet to hit tangible milestones by focusing on outcomes. My concern is that another raise in 6-9 months creates the same uncertainty with which has paralysed the company on the non clinical side over the last 12 months. It’s clear there is a strong case for this company but the material upside won’t happen till the pipeline has progressed further.
Thank you everyone for your contributions here. I’m not an expert in science / biotech and learn something new from every one of you each day.
CHM Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)